Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new dosing schedule tame steroid side effects in duchenne?

NCT ID NCT07787689

Disease control Sponsor: Muhammad Aamir Latif Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests two ways of taking the steroid prednisolone in boys aged 4-10 with Duchenne muscular dystrophy who can still walk. One group takes the drug every other day, while the other takes it for 10 days on, then 10 days off. The goal is to see which schedule better preserves muscle strength while reducing side effects like weight gain and high blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prednisolone
What this could lead to
If one dosing schedule works better, it could point to a safer way to preserve muscle strength in boys with Duchenne muscular dystrophy while reducing side effects.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. Prednisolone can cause weight gain, high blood sugar, and other side effects, and the optimal balance may still be unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 10 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients * Aged 4-10 years * 2\. Confirmed diagnosis of DMD (via genetic testing and significantly elevated creatine kinase (CK) levels \>1000 U/L with typical clinical presentation) Exclusion Criteria: * Patients with pre-existing cardiopulmonary failure * Patients entirely unable to perform baseline ambulatory assessments (non-ambulatory) * Patients with clinically suspected muscular dystrophy with normal genetic study for DMD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Duchenne muscular dystrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Duchenne muscular dystrophy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Children's Hospital/University of Child Health Sciences

    Lahore, Punjab Province, 54600, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.